SOPHIA ANTIPOLIS CEDEX, France, Sept. 27, 2013 (GLOBE NEWSWIRE) --
Nicox S.A. (NYSE Euronext Paris: COX) is attending the 2013 International Vision Expo & Conference, taking place from October 3 to 5, 2013 in Las Vegas, Nevada, United States. Nicox can be found at booth number MS2057. Nicox will have several members of its US operational team in attendance presenting AdenoPlus(®), a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis. AdenoPlus(®) was launched by Nicox in the US in October 2012 ................................... About Nicox Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus(®), a test for the differential diagnosis of acute conjunctivitis in- licensed from RPS(®). The Company's pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non- ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada). Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps). For more information please visit www.nicox.com . ................................... This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website ( www.nicox.com ) and on the AMF's website ( www.amf-france.org ). ................................... Contacts Nicox Gavin Spencer | Executive Vice President Corporate Development Tel +33 (0)4 97 24 53 00 | communications@nicox.com Media Relations FTI Consulting Europe Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263 Julia.Phillips@fticonsulting.com Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0) 7843 080947 Stephanie.Cuthbert@fticonsulting.com Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977 Mo.Noonan@fticonsulting.com Nicox attends Vision Expo West 2013 in Las Vegas: http://hugin.info/143509/R/1732009/579357.pdf [HUG#1732009]
